Regulatory News In Brief
Electro-shock controversy: Psychiatrists and skeptic patient advocacy groups remain split on the safety and efficacy of electroconvulsive shock therapy devices. After requiring manufacturers of certain "pre-amendment" Class III devices, including ECT devices, to submit safety and effectiveness information, FDA opened a docket to allow the public to weigh in as the agency decides whether to require PMAs for the devices or downclassify them (1"The Gray Sheet" Sept. 14, 2009). The psychiatric community maintains that ECT is a safe and effective treatment option for psychiatric disorders such as severe depression. "When patients are appropriately screened and ECT is appropriately delivered, there is no question about its efficacy in a significant percentage of very ill patients," Cleveland Clinic's Donald Malone, M.D., comments. "Requiring a PMA of the current ECT device companies would place a tremendous burden on relatively small companies." Others, such as the Center for Disability Rights, oppose down-regulation. Because of the "severe danger" of electro-shock, the procedure is banned in Texas for children under age 16, noted one psychologist who urged FDA to require PMAs for ECT devices. Though not a booming market, ECT is still used in some facilities; manufacturers include Mecta Corporation (SpECTrum) and Somatics (Thymatron)
More from Archive
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.
St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.
Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.
More from Medtech Insight
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
- • By
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.





